Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival ...

Explore See latest videos, charts and news Ado YOASOBI See latest videos, charts and news Scheduled to take place March 16, 2025, at the Peacock Theater in Los Angeles, California, the event will ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients with HER2-low or HER2-ultraow metastatic disease that progressed after endocrine therapy.

Recent trials demonstrated that adjuvant trastuzumab emtansine (T-DM1) had some improved outcomes compared to trastuzumab in early analysis. This study reported an updated final analysis of adjuvant T ...

It's the latest product from ADO (A Dece Oasis), an OEM that has slowly but very surely established itself as a reputable and highly innovative company on the mid-level segment. Air 30 Ultra ...

blockade with trastuzumab and pertuzumab with the current standard of care, taxane plus trastuzumab and pertuzumab, in HER2-positive metastatic breast cancer (MBC). Compared with the taxane-based ...